July 2022 Updates on ED Clinical Trials

And just like that, summer 2022 is halfway through! We have ongoing studies at three of our affiliate emergency departments and continue to engage them in new research opportunities. We have new research staff joining us this summer and fall—so you'll be some new faces. Please be patient and make them feel welcomed as they are aspiring to be in your shoes one day soon. Enjoy Oregon’s beautiful summer.

Bory Kea, MD, MCR, Director of Clinical Trials

For the interested reader, more details on the below research studies can be found at: http://www.ohsu.edu/oprem

---

**ACTIVE STUDIES**

<table>
<thead>
<tr>
<th>IVY-4</th>
<th>REASON3</th>
<th>ICECAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>GUIDED-HF</td>
<td>Compartment Syndrome</td>
<td>ACTIV-4a (AC-INPT)</td>
</tr>
<tr>
<td>ACTIV-4d (NECTAR)</td>
<td>PACT</td>
<td>BOOST-3</td>
</tr>
<tr>
<td>STRATIFY</td>
<td>KCENTRA</td>
<td>HydraSense</td>
</tr>
<tr>
<td>AF CDS</td>
<td>Fentalog (ToxIC)</td>
<td>Covid PreVent Trial (on hold)</td>
</tr>
<tr>
<td>FAST Exam</td>
<td>SAVE-O2</td>
<td></td>
</tr>
</tbody>
</table>

**IVY-4: Influenza and Other Viruses in the Acutely Ill**
Assessing the clinical validity of SARS-CoV-2 RT-PCR results and vaccine effectiveness

Launched: February 2022
Study Duration: February 2023
Sites: OHSU & Vanderbilt University Medical Center

- **PI:** Akram Khan, MD; **Coordinators:** PRISM Research Team
- **Inclusion:** acute symptom onset within 14 days of admission; positive or negative SARS-CoV-2, influenza, or RSV test after onset of symptoms
- **Exclusion:** test > 14 days of onset of symptoms, previously enrolled in surveillance program
- **Status:** ACTIVE, Enrolled: 280
- **Contact:** Akram Khan, khana@ohsu.edu; Minn Oh, ohmi@ohsu.edu

**Implementation of a Self-Care Plan for Patients with Acute Heart Failure Discharged from the ED (GUIDED-HF)**

GUIDED-HF is a multi-site project with implementation of a self-care plan for acute heart failure (HF) at OHSU and Hillsboro Medical Center. This project aims to provide self-care coaching (x3 virtual visits) for patients discharged from the Emergency Department (ED) with HF.
Launched: February 1, 2022
Sites: OHSU & HMC
- PI: Bory Kea; Study Coordinator: Joy Kim
- Inclusion: Diagnosed with HF and/or received loop diuretics in ED.
- Status: Enrolling; Enrolled: 13
- Contact: Joy Kim, kimjoy@ohsu.edu

ACTIV-4d (Novel Experimental COVID Therapies Affecting Host Response [NECTAR])
Evaluating therapies targeting host tissue and the renin-angiotensin-aldosterone system (RAAS) in hospitalized patients with COVID-19.

Launched: January 2022
Study Duration: January 2023
- PI: Akram Khan, MD; Coordinators: PRISM Research Team
- Inclusion: > 18 yo., COVID + and symptomatic, requiring oxygen support or SpO2 < 92, hospitalization period < 72 hours
- Exclusion: pregnant, breastfeeding, prisoners, end-stage renal team on dialysis, DNR/DNI
- Status: ACTIVE, Enrolled: 17
- Contact: Akram Khan, khana@ohsu.edu; Minn Oh, ohmi@ohsu.edu; page 11912

Tailored Dissemination and Implementation of Emergency Care Clinical Decision Support to Improve Emergency Department Disposition (STRATIFY)
STRATIFY is a study on the development and dissemination/implementation of a clinical decision support tool for heart failure risk stratification and disposition. This project aims to examine ED workflow at OHSU and Hillsboro Medical Center (HMC) to determine how to best integrate it into a clinical decision support (CDS) tool for patient and provider shared-decision making, specifically for acute heart failure patients.

- PI: Bory Kea; Study Coordinator: Joy Kim
- Status: Completed on-site visits → Analyzing retrospective EHR data using the STRATIFY risk factors to understand and address data challenges in STRATIFY implementation
- Contact: Joy Kim, kimjoy@ohsu.edu

Atrial Fibrillation (AF) Clinical Decision Support (CDS) Tool
A stepped-wedge clinical trial of an electronic clinical decision support tool to improve stroke prevention in patients with atrial fibrillation. Patients and providers will be recruited for qualitative interviews at 3 sites (OHSU, AHP, HMC).

Please use the clipboard function to copy documentation from the tool:
Automated Ultrasound Image Analysis of the Abdominal FAST Exam

The purpose of this study is to obtain a library of positive and negative abdominal ultrasound images of the standard Focused Assessment with Sonography for Trauma (FAST) imaging protocol, which can be subsequently annotated to train a machine learning algorithm.

Launched: October 13, 2021
Sites: OHSU, Medstar, Brook Army Medical Center, Tripler Army Medical Center, Womack Army Medical Center

- **PI:** Nikolai Schnittke; **Coordinators:** Samantha Underwood and Michael Fleming
- **Inclusion:** Adults ED trauma patients who either have a positive FAST exam performed and saved by the clinical team, or have a CT scan of the abdomen/pelvis performed as part of the trauma workup, with follow-up research FAST performed by the study team. Non-trauma patients with peritoneal fluid are also eligible for a research FAST exam performed by the study team.
- **Exclusion:** Skin disease and/or wounds that would preclude transducer placement, prisoners.
- **Status:** Enrolling; **Enrolled:** 60
- **Contact:** Nikolai Schnittke, schnittk@ohsu.edu

For potential enrollment please call or page TRG: 4-5939 pager: 11502

**REASON3: Bedside Cardiac Ultrasound in Cardiac Arrest**

The objective is to measure survival rates associated with different presenting rhythms as assessed by ultrasound versus ECG strip in patients presenting in cardiac arrest.

Launched: August 17, 2021

- **PI:** Nikolai Schnittke
- **Inclusions:** Adult ED patients in nontraumatic cardiac arrest
- **Exclusions:** Resuscitation ended due to end-of-life decisions, ultrasound images or rhythm strip not saved.
- **Status:** Enrolled; **Enrolled:** 6
- **Contact:** Nikolai Schnittke, schnittk@ohsu.edu
Observational Study of Extremity Compartment Syndrome Using SWE and MFI
An observational study to evaluate the utility of two ultrasound modes (shear wave elastography and microvascular flow imaging) in the diagnosis of compartment syndrome related to lower and/or upper extremity traumatic injury.

Launched: May 5, 2021
- PI: Kenton Gregory
- Inclusions: Adult ED patients with suspected (clinical suspicion and/or high-risk injury requiring scheduled compartment checks) single or multiple acute compartment syndrome of the lower and/or upper extremity.
- Exclusions: Prior fasciotomy of affected extremity, Skin disease and/or wounds that would preclude transducer placement, Prisoners.
- Status: Enrolling; Enrolled: 10
- Contact: Nikolai Schnittke, schnittk@ohsu.edu ; Bryson Hicks, hicksbr@ohsu.edu

For potential enrollment please call or page TRG: 4-5939 pager: 11502

PACT- Prehospital Airway Control Trial
PACT is an open-label, multi-site, stepped wedge randomized trial comparing a standard strategy of airway management with a strategy of first attempt with supraglottic airway (SGA) for trauma patients in a prehospital setting. The primary outcome is 24-hour mortality. It is assessed 24 hours after hospital arrival. Eight local agencies in the Clackamas and Washington counties are participating including AMR Clackamas, Clackamas County Fire District 1, Lake Oswego Fire, Molalla Fire, Canby Fire, Tualatin Valley Fire & Rescue, Hillsboro Fire & Rescue, and Metro West Ambulance.

Launched: April 1, 2021
- PI: Mo Daya, Co-I: Marty Schreiber Coordinator: Nancy Le, Sam Underwood
- Inclusion: Trauma requiring advanced airway management. Indicators of the need for advanced airway management include: a) GCS < 8, b) SpO2 < 90 despite supplemental oxygen, c) ETCO2 > 60 despite supplemental ventilation, or d) provider discretion. Transport to LITES Trauma Center – OHSU ONLY.
- Exclusion: <15 years of age, pregnant, prisoner, initial advanced airway attempted by a non-PACT agency, in cardiac arrest without ROSC at time of intervention, caustic substance ingestion, airway burns, objection to enrollment voiced by subject or family members at the scene.
- Status: Enrolling; Enrolled: 64
- Contact: Nancy Le, lena@ohsu.edu

**OHSU Team- please remember to document: (1) Date & Time of Airway Exchange and (2) Reason for Airway Exchange (hypoxia, inadequate ventilation, etc).**

KCENTRA
A multicenter, pre-hospital pilot trial to determine the feasibility and safety of Kcentra administration for the early treatment of patients with traumatic shock, compared to placebo, in the field. This study will be conducted under EFIC (Exception from Informed Consent).

Launched: March 2021 Sites: OHSU and sites at Houston (2) and Seattle (1)
- PI: Schreiber, Coordinator: Samantha Underwood
- Registered with ClinicalTrials.gov: NCT04019015
- FDA IND: Martin Schreiber, 18153
- Inclusion: 18 years and older, SBP <70 or no palpable pulse, suspicion of hemorrhagic shock, transport to participating hospital
- Status: On Hold
Predicting medical consequences of novel fentanyl analog overdose using the Toxicology Investigators Consortium (ToxIC)

Purpose of this multi-center study is molecular identification and quantitation of fentanyl analogues (fentalogs) in a prospective cohort of 1000 Emergency Department (ED) patients with opioid overdose (OD) from the established ToxIC hospital network. The number of subjects to be enrolled at each ToxIC site is approximately between 25-100. As an Exploratory Sub-Aim, we will characterize psychostimulant drug co-ingestions with fentalogs (e.g. synthetic cannabinoids, cocaine, cathinones, etc.) to provide confirmatory identification and quantitation.

Please use "poisoning by opioids" in your impression for all opioid overdoses.

Launched: November 2020

- **PI:** Adrienne Hughes; **Study Coordinator:** Joy Kim
- **Inclusion:** ED patient Opioid OD. Availability of waste blood or urine specimens for analysis.
- **Exclusion:** Age < 18 years. Non-toxicological diagnosis. Prisoners. Trauma/Burns.
- **Status:** Enrolling (resumed Feb 2022); **Enrolled:** 45
- **Contact:** Joy Kim, kimjoy@ohsu.edu

SAVE-O2 - Strategy to Avoid Excessive Oxygen for Critically Ill Trauma Patients

SAVE-O2 will be a multicenter cluster randomized, stepped wedge implementation trial of a multimodal educational intervention to target normoxia in adult trauma patients admitted to the intensive care unit (ICU). The goal is to improve oxygenation to >90% of eligible patient-hours spent in the desired normoxia range, excluding time without supplemental oxygen or time on FiO2 100% and below the normoxia range.

Launched: October 15, 2020

- **PI:** Schreiber, **Coordinator:** Samantha Underwood
- **Inclusion:** Patients who meet criteria for entry into the OHSU trauma registry
- **Exclusion:** Age <18 years, Prisoners, Known pregnancy, Transferred patients not admitted through the emergency department
- **Status:** Active
- **Contact:** Samantha Underwood, underwos@ohsu.edu

ICECAP- Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (a SIREN Network study)

This study will enroll comatose adult survivors of out of hospital cardiac arrest that have already been rapidly cooled using a definitive temperature control method.

Launched: September 2020 **Site:** Portland Adventist ED

- **ICECAP PI:** Daya, **ICECAP Co-I:** Julia Durrant (OHSU), Miko Enomoto (OHSU), Josh Lupton (OHSU & Portland Adventist), Marwan Mouammar (Portland Adventist), Matthew Neth (Portland Adventist), William Spurlock (Portland Adventist), **Coordinator:** Keeley McConnell
- **Registered with ClinicalTrials.gov:** NCT 04217551
- **FDA IDE:** William Meurer, G160072
- **Status:** Enrolling; **Enrolled:** 48; **All site total:** 501
- **Contact:** Keeley McConnell, mcconnke@ohsu.edu
ACTIV-4a (Antithrombotic Strategies in Hospitalized Adults with COVID-19 [AC-INPT])
Evaluating the effects of combining a P2Y12 inhibitor with anticoagulants for adults hospitalized for moderate to severe COVID-19. This is a continuation of the ACTIV-4 study, which evaluated prophylactic vs. therapeutic anticoagulation in adults hospitalized with COVID-19.

Launched: September 4, 2020  
Study Duration: December 2021

- **PI:** Akram Khan, MD ; **Coordinators:** PRISM Research Team  
- **Inclusion:** > 18 yo., COVID + and symptomatic, expected to require hospitalization for > 72 hours  
- **Exclusion:** comfort care, ICU level of care (including high flow), ventilated, pregnant, low platelet or hemoglobin counts, contraindication to anticoagulation (i.e. recent stroke, bleeding disorder)  
- **Status:** ACTIVE, Enrolled: 24  
- **Contact:** Akram Khan, khana@ohsu.edu ; Minn Oh, ohmi@ohsu.edu ; page 11912

BOOST-3 Brain Oxygen Optimization in Severe TBI Phase-3 Trial (a SIREN Network study)
BOOST 3 is a trial run through the nationwide SIREN Network. This study is comparing two strategies currently used for monitoring and treating patients with severe traumatic brain injury in the ICU. BOOST 3 allows for EFIC (Exception from Informed Consent) if an LAR is not present (within 6 hours).

Launched: March 16, 2020

- **BOOST-3 PI:** David Zonies, **SIREN PI:** Daya, **Coordinators:** Michael Seigneur (TRG), Jenny Cook EM Coordinator  
- **Registered with ClinicalTrials.gov:** NCT03754114  
- **Status:** Enrolling; **Enrolled:** OHSU: 22; All site total: 339  
- **Contact:** Michael Seigneur, seigneum@ohsu.edu

For more information: [https://www.ohsu.edu/school-of-medicine/emergency/boost-3-study](https://www.ohsu.edu/school-of-medicine/emergency/boost-3-study)

HydraSense for Sepsis

Launched: June 24, 2019

- **PI:** David Sheridan  
- **Status:** Data Analysis; **Enrolled:** 563 total, 123 sepsis enrollments  
- **Contact:** David Sheridan; sheridda@ohsu.edu

For more information: [https://www.ohsu.edu/school-of-medicine/emergency/boost-3-study](https://www.ohsu.edu/school-of-medicine/emergency/boost-3-study)

Digital Capillary Refill with HydraSense
Using a novel device (HydraSense) to compare manual vs digital capillary refill: currently enrolling in patients 6mo-65yo.

This study requires NO work or input from RNs or MDs. The study team will work around staff with any patients they enroll to make sure and prioritize your time with them over the study.

Launched: September 12, 2018
Covid PreVent Trial
Purpose: Evaluating a single treatment of very low dose thoracic radiation in patients with s/sx of severe COVID, but prior to intubation, to determine whether intubation can be avoided. Can be on other trials, get normal meds.

- PI: Ravi Chandra, Radiation Medicine
- Inclusion: >50 yo, s/sx severe COVID (fever, tachypnea, oxygen requirement), hospitalized and sx for less than 9 days
- Exclusion: Mechanical ventilation, prior RT or intrinsic pulmonary disease, CHF exacerbation within 6 months
- Status: On hold
- Contact: Ravi Chandra, chandrav@ohsu.edu

CLOSED STUDIES

Clinical Evaluation of the BinaxNOW® COVID-19 Ag / Flu A & B Combo Card
Objective: To estimate the clinical sensitivity and specificity of the BinaxNOW® Ag Combo card against the reference method, Abbott RealTime SARS-CoV-2/Flu A & B, in patients suspected of COVID-19/Flu A & B infection by any healthcare provider (RN, NP, PA, or MD) using nasal swabs. Staff will collect 2 nasal swabs from each subject. One of the swabs will be shipped to the Sponsor’s central laboratory for reference testing, while the other will be tested within 5 minutes of collection on the rapid AG COMBO card.

Launch: TBD Sites: OHSU & Adventist

Study coordinators will check with clinical staff on suspected COVID-19/Flu A & B patients between Monday – Thursday from 8:00-2:00 PM.

- PI: Bory Kea; Coordinator: Keeley McConnell
- Inclusion: Subject is suspected of COVID-19/FLU A & B infection by a healthcare provider.
- Exclusion: Subject is ≥ eight (8) days from symptom onset, Subjects with active nose bleeds or acute facial injuries/trauma, use of topical nostril treatments within 24 hours, nasal wash within the last 2 hours, currently enrolled in a study to evaluate an investigational drug, already participated in this study, unable/unwilling to provide informed consent, vulnerable populations (prisoners and pregnant woman).
- Status: Closed Enrolled: 0
- Contact: Keeley McConnell, Senior Clinical Research Coordinator: mcconnke@ohsu.edu

ACTIV-3 (Therapeutics for Inpatients with COVID-19 [TICO])
A platform designed for testing therapeutic monoclonal antibody agents for adults hospitalized for COVID-19

Launched: August 4, 2020
Study Duration: July 2022

- PI: Akram Khan, MD; Coordinators: PRISM Research Team
- Inclusion: > 18 yo, COVID + and symptomatic (< 12 days)
- Exclusion: received convalescent plasma, serious condition(s) present at enrollment (i.e. stroke, meningitis, encephalitis, congestive heart failure, DVT or PE)
Clinical Evaluation of the BinaxNOW® COVID-19 Antigen (Ag) Card

Objective: To estimate the clinical sensitivity and specificity of the BinaxNOW® COVID-19 Ag card against the reference method, Abbott RealTime SARS-CoV-2, in patients suspected of COVID-19 infection by any healthcare provider (RN, NP, PA, or MD) using nasal swabs. Staff will collect 2 nasal swabs from each subject. Swabs will be shipped to the Sponsor’s central laboratory for reference testing.

Launched: August 2020 Sites: OHSU & Adventist

Study coordinators will check with clinical staff on suspected COVID-19 patients (there is no time limit on symptom duration) between Monday – Friday from 9:00-4:00 PM.

- **PI:** Bory Kea; **Coordinator:** Keeley McConnell
- **Inclusion:** Subject is suspected of COVID-19 infection by a healthcare provider.
- **Exclusion:** Subjects with active nose bleeds or acute facial injuries/trauma, currently enrolled in a study to evaluate an investigational drug, already participated in this study, unable/unwilling to provide informed consent, vulnerable populations (prisoners and pregnant woman).
- **Status:** Closed; **Enrolled:** 312
- **Contact:** Keeley McConnell, Senior Clinical Research Coordinator: mcconnke@ohsu.edu